Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
about
Chagas disease: "the new HIV/AIDS of the Americas"Structure of the Trypanosoma cruzi protein tyrosine phosphatase TcPTP1, a potential therapeutic target for Chagas’ diseaseModulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas diseaseCongenital Chagas disease: recommendations for diagnosis, treatment and control of newborns, siblings and pregnant womenSafety Profile of Nifurtimox for Treatment of Chagas Disease in the United StatesTolerance of benznidazole in treatment of Chagas' disease in adultsIn vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compoundsPopulation pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adultsRuthenium complex with benznidazole and nitric oxide as a new candidate for the treatment of chagas diseaseMachine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug DiscoveryUtilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas DiseaseProteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sicknessEffects of astaxanthin in mice acutely infected with Trypanosoma cruziScaffold proteins LACK and TRACK as potential drug targets in kinetoplastid parasites: Development of inhibitorsRepurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids.Multicenter epidemiological and clinical study on imported Chagas diseases in Alicante, Spain.Prediction Models for Decision-Making on Chagas Disease.Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatmentScreening of Potential anti-Trypanosoma cruzi Candidates: In Vitro and In Vivo Studies.Methodological advances in drug discovery for Chagas disease.Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome.In vitro and in vivo trypanocidal effects of the cyclopalladated compound 7a, a drug candidate for treatment of Chagas' disease.Current and developing therapeutic agents in the treatment of Chagas diseaseIs Chagas disease really the "new HIV/AIDS of the Americas"?A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazoleAchievements and challenges upon the implementation of a program for national control of congenital Chagas in Bolivia: results 2004-2009.Arthritis and benznidazole: more closely related than we thought.Lead identification to clinical candidate selection: drugs for Chagas disease.In vitro screening for drug repositioning.Population pharmacokinetics of benznidazole in adult patients with Chagas disease.Clinical aspects of Chagas disease and implications for novel therapies.First Documented Transmission of Trypanosoma cruzi Infection through Blood Transfusion in a Child with Sickle-Cell Disease in Belgium.Therapy of chagas disease: implications for levels of prevention.Toxic Profile of Benznidazole in Patients with Chronic Chagas Disease: Risk Factors and Comparison of the Product from Two Different Manufacturers.Molecular characterization of the hexose transporter gene in benznidazole resistant and susceptible populations of Trypanosoma cruzi.Improving access to Chagas disease diagnosis and etiologic treatment in remote rural communities of the Argentine Chaco through strengthened primary health care and broad social participationLow-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease.New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult PatientsSerological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina
P2860
Q21144502-F94F8CAB-89A0-4461-909D-B6BCFBC231A5Q27675033-3A664F54-21E7-47B4-A4D4-2CABAEBADBF3Q28083346-63893C8B-44AB-4F46-93AF-7B443A9BCA9DQ28251886-E2249F70-4CCA-461A-A802-55D129847359Q28277238-88DBAA02-39BF-41F8-B0A2-CBEA94525743Q28292605-5F899E31-DA28-4B2B-8ABB-8E88D6A9D31EQ28474813-893C7576-8991-4BAC-A6AA-B161C21F9C7FQ28539049-1AA8CBB4-C30C-4CC6-9D0C-CB340502CC96Q28543494-995C4D84-F71F-4CB0-9F47-63CED000BE61Q28545842-1220E993-9B22-4A32-8B11-AA18AB23D78AQ28546644-884523C4-AB71-4BC8-BECE-83962F90EA16Q28817181-B517021B-ACE9-4B27-828D-407C41E93245Q30096798-A388B08A-3F3E-4EEE-9D59-1D23D89B4A05Q30359734-16255539-4E56-4378-837D-89C905A988F0Q30487641-FAFC7BD5-5BDB-4AA5-A364-764E30812543Q33162074-892C2855-CC16-47D4-A5CA-89ECF787D928Q33728836-6F336DC9-9521-49FE-B603-880C13C6F0DAQ33762602-BC670902-18AB-43DE-9E07-D3BC2773599FQ33918063-FBF1471E-6444-4256-8561-849F92F17027Q33945347-EBDA55DC-D84D-4EC5-9E67-DDC3B9965D4EQ33955428-5605DEE4-72EA-497A-9AE9-56BD7C531E76Q34045200-F8BA7169-FE31-4DC9-8DA1-F97B0434BFD6Q34170132-96E3DC20-2001-477F-B226-97F56D1368D9Q34474584-FAF42225-348C-483B-9A32-8D063B59D78EQ34596630-75252790-A5D4-4533-B2A9-CE2DDD5FBBB0Q34855240-0640D28D-4CAA-4A08-93B8-DEE7EA00200FQ34923301-7AA10904-C3CA-4223-8CCD-337AE0AB9DBCQ35301205-B5743808-9E61-4D32-A847-A275856C0C07Q35531225-AB9F68FE-FE8C-4312-9C36-8A00D1FCCD6FQ35607812-7DC07D45-D8AF-41A4-98AA-4D28D7451493Q35676177-F0C9D6B8-25E9-4770-A78A-7232B3880C24Q35808368-2D3FFB0E-B20F-45ED-BC51-A55C5061F9DDQ35864834-7E2D7E19-3DFD-43DC-AFD4-FE76B7DDAF44Q36076071-BC8F90DE-800C-4081-88F9-1F2F1B3A5133Q36200672-1E4A53F3-09AE-4AD2-B509-4C9C4B00129AQ36278397-C4487453-796D-43F8-B525-62DDBDD8AC69Q36446085-BAC8FE13-DAD9-4492-BF20-62124330024FQ36505372-D0FCA484-BC4E-4416-8E7B-F59CA5857561Q36571807-A3E9B26F-297A-4F8E-BA57-577489123C88Q37007518-DC42DF56-A74D-4A62-AA6E-474A85291269
P2860
Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
@en
Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
@nl
type
label
Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
@en
Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
@nl
prefLabel
Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
@en
Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
@nl
P2093
P2860
P356
P1476
Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
@en
P2093
Alejandro Armenti
Bruno Lococo
Carlos Vigliano
Graciela Bertocchi
Marcos Petti
Maria Gabriela Alvarez
Rodolfo Viotti
P2860
P304
P356
10.1586/14787210.7.2.157
P5008
P577
2009-03-01T00:00:00Z